TOP TEN perturbations for 40036_at (Homo sapiens)

Organism: Homo sapiens
Gene: 40036_at
Selected probe(set): 210093_s_at
Platform: Affymetrix Human Genome U133 Plus 2.0 Array

Expression of 40036_at (210093_s_at) across 6674 perturbations tested by GENEVESTIGATOR:

B-CLL study 11 (DMSO) / vehicle (DMSO) treated normal T-cell sample

Relative Expression (log2-ratio):-3.530717
Number of Samples:4 / 4
Experimental B-CLL study 11 (DMSO)
Peripheral blood mononuclear cells (PBMCs) obtained from chronic lymphocytic leukemia (CLL) patients and in vitro treated with vehicle (DMSO) for 4 hours. PBMCs’ samples contained 90% CD19+ CD5+ B lineage CLL cells (B-CLL). Inclusion criteria: untreated CLL patients or at least 1 month after chemotherapy. Exclusion criteria: patients with active infections or other serious medical conditions or with white blood cell (WBC) counts of 15,000/l.
Control vehicle (DMSO) treated normal T-cell sample
MACS purified T-cells from healthy donor peripheral blood treated with vehicle (DMSO) for 4 hours.

B-CLL study 11 (rolipram) / rolipram study 4 (normal T-cell; 20uM)

Relative Expression (log2-ratio):-3.2772408
Number of Samples:4 / 4
Experimental B-CLL study 11 (rolipram)
Peripheral blood mononuclear cells (PBMCs) obtained from chronic lymphocytic leukemia (CLL) patients and in vitro treated with rolipram (20 uM, cyclic nucleotide phosphodiesterase (PDE4) inhibitor) for 4 hours. PBMCs’ samples contained 90% CD19+ CD5+ B lineage CLL cells (B-CLL). Inclusion criteria: untreated CLL patients or at least 1 month after chemotherapy. Exclusion criteria: patients with active infections or other serious medical conditions or with white blood cell (WBC) counts of 15,000/l. ATC code:---
Control rolipram study 4 (normal T-cell; 20uM)
MACS purified T-cells from healthy donor peripheral blood treated with rolipram (20 uM, cyclic nucleotide phosphodiesterase (PDE4) inhibitor) for 4 hours. ATC code:---

B-CLL study 11 (DMSO) / vehicle (DMSO) treated normal B-cell sample

Relative Expression (log2-ratio):-2.3711061
Number of Samples:4 / 4
Experimental B-CLL study 11 (DMSO)
Peripheral blood mononuclear cells (PBMCs) obtained from chronic lymphocytic leukemia (CLL) patients and in vitro treated with vehicle (DMSO) for 4 hours. PBMCs’ samples contained 90% CD19+ CD5+ B lineage CLL cells (B-CLL). Inclusion criteria: untreated CLL patients or at least 1 month after chemotherapy. Exclusion criteria: patients with active infections or other serious medical conditions or with white blood cell (WBC) counts of 15,000/l.
Control vehicle (DMSO) treated normal B-cell sample
MACS purified resting B-cells from healthy donor peripheral blood treated with vehicle (DMSO) for 4 hours.

glioma study 27 (glioblastoma, NOS) / glioma study 27 (pilocytic astrocytoma)

Relative Expression (log2-ratio):2.250123
Number of Samples:4 / 2
Experimental glioma study 27 (glioblastoma, NOS)
Primary tumor samples from resected brain tissues of patients with glioblastoma, NOS(WHO grade IV astrocytoma).
Control glioma study 27 (pilocytic astrocytoma)
Primary tumor samples from resected brain tissues of patients with pilocytic astrocytoma (WHO grade I astrocytoma).

nephroblastoma study 2 / normal kidney tissue (adult)

Relative Expression (log2-ratio):2.2474613
Number of Samples:4 / 3
Experimental nephroblastoma study 2
Tumor tissue samples from the kidney of patients with Wilms’ tumor.
Control normal kidney tissue (adult)
Normal adult kidney tissue samples.

scleroderma study 8 (blood; anifrolumab; 1mg/kg/wk; multiple dose; 56d) / scleroderma study 8 (blood; baseline; 1mg/kg/wk; multiple dose)

Relative Expression (log2-ratio):2.1437502
Number of Samples:4 / 4
Experimental scleroderma study 8 (blood; anifrolumab; 1mg/kg/wk; multiple dose; 56d)
Whole blood samples collected from adult systemic sclerosis patients at day 56 after a 4-week repeated intravenous injection of anifrolumab (1 mg/kg per week). Anifrolumab (MEDI-546) is a human IgG1κ mAb directed against subunit 1 of the type I IFN receptor. The patients were enrolled in a Phase 1 open-label clinical trial (study MI-CP180; NCT00930683). Further patient characteristics: Mean age (y): 49.3 ± 9.5; Mean weight (kg): 75.9 ± 33.7; Mean modified Rodnan Skin Score (mRSS): 24.5 ± 10.1. ATC code:---
Control scleroderma study 8 (blood; baseline; 1mg/kg/wk; multiple dose)
Whole blood samples from adult systemic sclerosis patients before a 4-week repeated intravenous injection of anifrolumab (1 mg/kg per week). Anifrolumab (MEDI-546) is a human IgG1κ mAb directed against subunit 1 of the type I IFN receptor. The patients were enrolled in a Phase 1 open-label clinical trial (study MI-CP180; NCT00930683). Further patient characteristics: Mean age (y): 49.3 ± 9.5; Mean weight (kg): 75.9 ± 33.7; Mean modified Rodnan Skin Score (mRSS): 24.5 ± 10.1.

B-CLL study 11 (rolipram) / rolipram study 4 (normal B-cell; 20uM)

Relative Expression (log2-ratio):-2.0436182
Number of Samples:4 / 4
Experimental B-CLL study 11 (rolipram)
Peripheral blood mononuclear cells (PBMCs) obtained from chronic lymphocytic leukemia (CLL) patients and in vitro treated with rolipram (20 uM, cyclic nucleotide phosphodiesterase (PDE4) inhibitor) for 4 hours. PBMCs’ samples contained 90% CD19+ CD5+ B lineage CLL cells (B-CLL). Inclusion criteria: untreated CLL patients or at least 1 month after chemotherapy. Exclusion criteria: patients with active infections or other serious medical conditions or with white blood cell (WBC) counts of 15,000/l. ATC code:---
Control rolipram study 4 (normal B-cell; 20uM)
MACS purified resting B-cells from healthy donor peripheral blood treated with rolipram (20 uM, cyclic nucleotide phosphodiesterase (PDE4) inhibitor) for 4 hours. ATC code:---

brefeldin A study 1 (0.5ug/ml; HCT 116) / untreated HCT 116 cell sample

Relative Expression (log2-ratio):1.9410973
Number of Samples:3 / 3
Experimental brefeldin A study 1 (0.5ug/ml; HCT 116)
Human colon carcinoma cell line HCT116 was treated with 0.5 ug/ml brefeldin-A for 24 hours in McCOYs 5A medium supplemented with 10% heat inactivated FBS. ATC code:---
Control untreated HCT 116 cell sample
Human colon carcinoma cell line HCT116 was grown in McCOYs 5A medium supplemented with 10% heat inactivated FBS.

diabetes type 2 study 14 (diabetic) / non-diabetic omental adipose tissue

Relative Expression (log2-ratio):-1.9072552
Number of Samples:11 / 6
Experimental diabetes type 2 study 14 (diabetic)
Omental adipose tissue of morbidly obese (BMI ≥ 40 kg/m2) African-American individuals with type 2 diabetes.
Control non-diabetic omental adipose tissue
Omental adipose tissue of morbidly obese (BMI ≥ 40 kg/m2) African-American individuals without type 2 diabetes.

T-cell activation study 1 / quiescent CD4+ T-cell sample

Relative Expression (log2-ratio):1.8249245
Number of Samples:2 / 2
Experimental T-cell activation study 1
CD4+ T-cell samples derived from PBMC´s of HIV-seronegative donors were activated with plate bound CD3 (1ug/ml) and soluble CD28 (50ng/ml) for 1 day.
Control quiescent CD4+ T-cell sample
Quiescent CD4+ T-cell samples derived from PBMC´s of HIV-seronegative donors.